02:33 , Jul 13, 2019 |  BioCentury  |  Finance

How crossover, insider support and big money correlated with performance across 1H19 IPOs

The performance of 1H19 IPOs point toward a continuation of a dual-class system where biotechs backed by deep-pocketed VCs and crossover investors can tap the public market at will and generate stronger after-market performance than...
01:58 , Jun 29, 2019 |  BioCentury  |  Finance

Biotech backs down in 2Q19

In a reversal from 1Q19, biotech stocks across all market cap tiers fell in the second quarter, leading to a total loss of $22.3 billion. However, the year-to-date change in market cap remains well in...
01:21 , Jun 28, 2019 |  BC Extra  |  Financial News

IPO window wide open: BridgeBio leads new listings with year’s largest

Four companies have debuted with upsized NASDAQ offerings in the past 24 hours, including the year's largest, to continue June's torrid IPO pace as 1H19 draws to a close. BridgeBio, Adaptive and Morphic all saw...
00:09 , Jun 27, 2019 |  BC Extra  |  Financial News

June 26 Financial Quick Takes: Adaptive prices upsized IPO; plus BridgeBio, Medicines Co., Global Blood, Odonate

Adaptive raises $300M in IPO  Adaptive Biotechnologies Inc. (NASDAQ:ADPT) raised $300 million through the sale of 15 million shares at $20 in an IPO on NASDAQ. The deal price values the computation immunology and diagnostics...
22:58 , Jun 18, 2019 |  BC Extra  |  Financial News

June 18 Financial Quick Takes: Biohaven sinks on fund-raising news; plus IPO trio sets terms

Amid buyout rumors, Biohaven proposes follow-on  Biohaven Pharmaceutical Holding Co. Ltd. (NYSE:BHVN) lost $13.54 (24%) to $43.83 on Tuesday, shedding more than half a billion dollars in market cap, after it proposed to raise $300...
20:36 , May 31, 2019 |  BC Extra  |  Financial News

New IPO filings include Adaptive, Morphic

Immunosequencing company Adaptive and integrin company Morphic each filed for IPOs on NASDAQ Thursday, while antipsychotic therapy developer Karuna revealed details of its planned listing on the exchange on Friday. Adaptive Biotechnologies Corp. (Seattle, Wash.)...
10:08 , Apr 30, 2019 |  BioCentury  |  Finance

How Nextech-led round will help Vividion to POC

After identifying three lead programs with its proteome-wide small molecule screening platform, San Diego-based Vividion has raised $82 million in an oversubscribed series B round led by new investor Nextech Invest. Now flush with over...
01:10 , Mar 2, 2019 |  BioCentury  |  Product Development

Roche broadens its BD scope

Roche’s proposed acquisition of Spark Therapeutics Inc. is the pharma’s first major deal since James Sabry took over partnering, and could be a glimpse of what’s to come as the pharma broadens its horizons on...
17:01 , Jan 11, 2019 |  BC Week In Review  |  Company News

Genentech, Adaptive Biotechnologies to develop cancer T cell therapies

Adaptive Biotechnologies Corp. (Seattle, Wash.) and Genentech Inc. partnered to develop personalized and off-the-shelf T cell therapies for a broad range of cancers using Adaptive's TruTCR discovery and immune profiling platform. TruTCR combines immunosequencing, cellular...
20:51 , Jan 4, 2019 |  BC Extra  |  Company News

Genentech, Adaptive Biotechnologies to develop cancer T cell therapies

Adaptive Biotechnologies Corp. (Seattle, Wash.) and Genentech Inc. partnered to develop personalized and off-the-shelf T cell therapies for a broad range of cancers using Adaptive's TruTCR discovery and immune profiling platform. TruTCR combines immunosequencing, cellular...